Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-05-19

FDA Approved: IBSRELA — Supplemental Application (Ardelyx, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for IBSRELA (tenapanor hydrochloride) from Ardelyx, Inc., likely updating labeling or expanding its indication for i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IBSRELA (tenapanor hydrochloride)

Snippet

SUPPL AP for IBSRELA (TENAPANOR HYDROCHLORIDE)